Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

How can deep learning impact healthcare?

“Genomic medicine really needs deep learning,” these were the words of keynote speaker Brendan Frey, CEO Deep Genomics at RE-WORK’s Deep Learning in Healthcare Summit 2016.

8 Apr 2016

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

SCIEX, a global leader in life science analytical technologies, and QPS Holdings, LLC (QPS), a leading global full-service Contract Research Organization (CRO), today announced a collaboration to advance Hybrid LBA –LCMS, a workflow for routine biologics quantification. Under the agreement, QPS Holdings will deploy the SCIEX BioBA Solution, the first end-to-end and most complete solution for bioanalysis of biologics.

6 Apr 2016

AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms

AXT has recently bolstered their preclinical and translational imaging products portfolio with the addition of inviCRO’s innovative software platforms.

From AXT Pty Ltd 5 Apr 2016

Vanderbilt, Celgene collaborate to accelerate development of personalized therapies

Vanderbilt University Medical Center has entered into a strategic research agreement with Celgene Corporation, a biopharmaceutical company based in Summit, New Jersey.

5 Apr 2016

Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, the Medical Research Council and the University of Cambridge

FEI (NASDAQ: FEIC) has partnered with five pharmaceutical companies: Astex Pharmaceuticals, AstraZeneca, GlaxoSmithKline, Heptares Therapeutics, and UCB; the Medical Research Council Laboratory of Molecular Biology (MRC-LMB); and the University of Cambridge’s Nanoscience Centre, to form the “Cambridge Pharmaceutical Cryo-EM Consortium,” which is the first of its kind worldwide.

From Thermo Fisher Scientific – Electron Microscopy Solutions 4 Apr 2016

Deep Learning in Healthcare Summit taking place in London

As the fifth global RE•WORK conference focused on artificial intelligence, the Deep Learning in Healthcare Summit will bring together industry, academia and startups to explore revolutionary deep learning tools and techniques that are shaping the future of medicine, healthcare and diagnostics.

30 Mar 2016

UTA chemists design efficient water-based system for synthesis of organic compounds

Chemists at The University of Texas at Arlington have devised a safer, more environmentally friendly, less expensive and more efficient water-based system for the synthesis of organic compounds typically used in pharmaceuticals, agrochemicals, cosmetics, plastics, textiles and household chemicals.

29 Mar 2016

Researchers develop metastasis-on-a-chip system to advance cancer investigation, drug discovery

Advances in personalized medicine allow doctors to select the most promising drugs for certain types of malignant tumors.

24 Mar 2016

FEI, NovAliX to jointly provide cryo-EM-based structural analysis services for pharmaceutical and biotech industry

FEI and NovAliX, a contract research organization (CRO), announced today a strategic partnership to enable NovAliX to provide commercial cryo-electron microscopy (EM)-based structural analysis services to its customers in the pharmaceutical and biotech industry.

From Thermo Fisher Scientific – Electron Microscopy Solutions 23 Mar 2016

Computer-assisted methods may help as decision support system to combat Zika virus

Global climate change, international travel, and ineffective vector control programs are aiding the emergence of infectious diseases globally. The currently expanding Zika virus (ZIKV) epidemic is one such problem.

21 Mar 2016

Novel compound shows promise as potential treatment for acute myeloid leukemia

A novel compound has shown promise in preclinical studies as a treatment for acute myeloid leukemia, more than doubling median days of survival even in a drug-resistant form of the disease.

21 Mar 2016

Bruker showcases innovative NMR solutions for pharmaceutical industry at ENC 2015

At the 56th Experimental Nuclear Magnetic Resonance Conference, Bruker this week is show-casing several innovative drug discovery, drug development and process control solutions for small molecule NMR characterization in the pharmaceutical industry.

From Bruker BioSpin Group 15 Mar 2016

NIH-funded investigators develop therapeutic compound effective against malaria

An international team that includes NIH-funded researchers at Stanford University has developed a therapeutic compound that is effective in inhibiting Plasmodium falciparum, one of five species of parasite that infects people with malaria, and the strain which causes the highest number of malaria deaths.

13 Mar 2016

Novel nanoparticle technology can decipher protein structures and help access drug targets

Researchers at Karolinska Institutet, Sweden, have developed a nanoparticle technology that can be used to stabilise membrane proteins so that their structure can be studied in a lipid environment. The method, described in Nature Methods, makes it possible to access drug targets that previously could not be investigated and therefore potentially allows for the development of novel drugs, therapeutic antibodies and vaccines.

9 Mar 2016

Genetic errors may reduce heart attack risk, study finds

To reduce risk of heart attack, the benefits of a healthy lifestyle are clear. But genetics can still stack the deck. Some people's genes bestow a natural advantage — or disadvantage — in protecting against heart disease, the leading cause of death worldwide.

3 Mar 2016

Beta blockers may improve effectiveness of triple negative breast cancer treatments

New research published in the March 2016 issue of The FASEB Journal, shows that a commonly prescribed class of high blood pressure drugs may have the potential to slow the growth of triple negative breast cancer tumors. These drugs, called "beta blockers" work by counteracting the pro-growth effect caused by adrenaline by affecting the the beta2-adrenoceptor.

2 Mar 2016

New screening technique to test drug compounds used in Ewing sarcoma treatment

In Ewing sarcoma, cancer cells' DNA is unwound abnormally from a condensed, compact state. Once sections of genetic code are open, key genes are turned on to help direct aggressive and cancerous cell growth.

1 Mar 2016

Novel therapeutic approach to target monomeric Tau protein

Dementia and other tauopathies, most notably Alzheimer's disease, embody a class of neurodegenerative diseases associated with the aggregation of the Tau protein in the human brain. These diseases represent one of the leading causes of death and disability in the elderly population in the western world, with no current effective therapy.

27 Feb 2016

Caribou Biosciences grants IDT worldwide rights to commercialize CRISPR-Cas9 reagents

Caribou Biosciences, Inc., a developer of CRISPR technologies for precision cell engineering, and Integrated DNA Technologies, Inc., a producer of custom synthetic oligonucleotide-based technologies for genomics applications, have entered into a non-exclusive license agreement under which Caribou has granted IDT worldwide rights to commercialize CRISPR-Cas9 reagents under Caribou’s intellectual property.

24 Feb 2016

Study could pave way for new treatment strategies for PKU

Phenylketonuria, also known as PKU, is the most common inherited disease affecting amino acid metabolism. Children are tested for PKU at birth, and babies diagnosed with the disease must adhere to a highly restricted diet to prevent permanent intellectual impairment.

16 Feb 2016

Drug Discovery News and Research

Further Reading

How can deep learning impact healthcare?

SCIEX and QPS Holdings enter collaboration to establish the BioBA solution for bioanalysis of biologics

AXT expands preclinical imaging portfolio with addition of inviCRO’s innovative software platforms

Vanderbilt, Celgene collaborate to accelerate development of personalized therapies

Cambridge Pharmaceutical Cryo-EM Consortium formed by FEI, five pharmaceutical companies, the Medical Research Council and the University of Cambridge

Deep Learning in Healthcare Summit taking place in London

UTA chemists design efficient water-based system for synthesis of organic compounds

Researchers develop metastasis-on-a-chip system to advance cancer investigation, drug discovery

FEI, NovAliX to jointly provide cryo-EM-based structural analysis services for pharmaceutical and biotech industry

Computer-assisted methods may help as decision support system to combat Zika virus

Novel compound shows promise as potential treatment for acute myeloid leukemia

Bruker showcases innovative NMR solutions for pharmaceutical industry at ENC 2015

NIH-funded investigators develop therapeutic compound effective against malaria

Novel nanoparticle technology can decipher protein structures and help access drug targets

Genetic errors may reduce heart attack risk, study finds

Beta blockers may improve effectiveness of triple negative breast cancer treatments

New screening technique to test drug compounds used in Ewing sarcoma treatment

Novel therapeutic approach to target monomeric Tau protein

Caribou Biosciences grants IDT worldwide rights to commercialize CRISPR-Cas9 reagents

Study could pave way for new treatment strategies for PKU

Biologics, Immunogenicity and Drug Discovery eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo